Who should own market access?
Today, market access is no longer a solo responsibility. Access outcomes are shaped by decisions made across nearly every corporate function—from R&D to regulatory to trade and channel to field reimbursement.
Yet many organizations still operate in silos, acquiring “access debt.” Every decision can create reimbursement, affordability, or distribution barriers that don’t emerge until launch.
In this article, President of Market Access & Value, Jen Norton, explores:
- Why access collaboration alone is no longer enough
- What access debt is and how it accumulates years before launch
- Where pre-launch handoffs commonly break down
- Why coverage isn’t the finish line
- How to implement true access accountability
Learn how organizations can better connect decisions across the product lifecycle and turn coverage into utilization, demand, and true patient access.
Author
Jen leads EVERSANA’s market access, pricing, and reimbursement strategies, helping life sciences innovators overcome barriers to drug access and affordability. With more than two decades of leadership in the pharmaceutical market access landscape, Jen…